<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Avecho Biotechnology Limited — News on 6ix</title>
    <link>https://6ix.com/company/avecho-biotechnology-ltd</link>
    <description>Latest news and press releases for Avecho Biotechnology Limited on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 12 May 2026 05:15:08 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/avecho-biotechnology-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836614578dffbe2df15bea7.webp</url>
      <title>Avecho Biotechnology Limited</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd</link>
    </image>
    <item>
      <title>Expiry of Listed Options</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/expiry-of-listed-options</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/expiry-of-listed-options</guid>
      <pubDate>Tue, 12 May 2026 05:15:08 GMT</pubDate>
      <description>Expiry of Listed Options</description>
    </item>
    <item>
      <title>March 2026 Quarterly Activities Report &amp; Appendix 4C</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/march-2026-quarterly-activities-report-and-appendix-4c-5</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/march-2026-quarterly-activities-report-and-appendix-4c-5</guid>
      <pubDate>Wed, 29 Apr 2026 02:53:18 GMT</pubDate>
      <description>March 2026 Quarterly Activities Report &amp; Appendix 4C</description>
    </item>
    <item>
      <title>Avecho completes recruitment for Phase III interim analysis</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/avecho-completes-recruitment-for-phase-iii-interim-analysis</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/avecho-completes-recruitment-for-phase-iii-interim-analysis</guid>
      <pubDate>Mon, 02 Mar 2026 03:43:17 GMT</pubDate>
      <description>Avecho completes recruitment for Phase III interim analysis</description>
    </item>
    <item>
      <title>Annual Report 31 December 2025</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/annual-report-31-december-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/annual-report-31-december-2025</guid>
      <pubDate>Fri, 27 Feb 2026 10:25:09 GMT</pubDate>
      <description>Annual Report 31 December 2025</description>
    </item>
    <item>
      <title>December 2025 Quarterly Activities Report &amp; Appendix 4C</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/december-2025-quarterly-activities-report-and-appendix-4c-5</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/december-2025-quarterly-activities-report-and-appendix-4c-5</guid>
      <pubDate>Thu, 29 Jan 2026 08:15:08 GMT</pubDate>
      <description>December 2025 Quarterly Activities Report &amp; Appendix 4C</description>
    </item>
    <item>
      <title>Phase III CBD Clinical Trial Recruitment Update</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/phase-iii-cbd-clinical-trial-recruitment-update</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/phase-iii-cbd-clinical-trial-recruitment-update</guid>
      <pubDate>Thu, 18 Dec 2025 04:53:13 GMT</pubDate>
      <description>Phase III CBD Clinical Trial Recruitment Update</description>
    </item>
    <item>
      <title>AVE Secures US &amp; EU Patent Allowances for CBD Soft-Gel</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/ave-secures-us-and-eu-patent-allowances-for-cbd-soft-gel</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/ave-secures-us-and-eu-patent-allowances-for-cbd-soft-gel</guid>
      <pubDate>Wed, 03 Dec 2025 05:53:02 GMT</pubDate>
      <description>AVE Secures US &amp; EU Patent Allowances for CBD Soft-Gel</description>
    </item>
    <item>
      <title>September 2025 Quarterly Activities Report &amp; Appendix 4C</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/september-2025-quarterly-activities-report-and-appendix-4c-5</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/september-2025-quarterly-activities-report-and-appendix-4c-5</guid>
      <pubDate>Fri, 31 Oct 2025 06:16:05 GMT</pubDate>
      <description>September 2025 Quarterly Activities Report &amp; Appendix 4C</description>
    </item>
    <item>
      <title>Avecho raises $2.5m via placement</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/avecho-raises-dollar25m-via-placement</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/avecho-raises-dollar25m-via-placement</guid>
      <pubDate>Thu, 23 Oct 2025 02:15:14 GMT</pubDate>
      <description>Avecho raises $2.5m via placement</description>
    </item>
    <item>
      <title>Appendix 4D and Half-year Financial Report</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/appendix-4d-and-half-year-financial-report-92</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/appendix-4d-and-half-year-financial-report-92</guid>
      <pubDate>Thu, 28 Aug 2025 09:37:16 GMT</pubDate>
      <description>Appendix 4D and Half-year Financial Report</description>
    </item>
    <item>
      <title>Sleep Health Week: Researchers Recruiting Now for CBD Insomnia Trial</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/sleep-health-week-researchers-recruiting-now-for-cbd-insomnia-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/sleep-health-week-researchers-recruiting-now-for-cbd-insomnia-trial</guid>
      <pubDate>Tue, 12 Aug 2025 00:32:00 GMT</pubDate>
      <description>Avecho Biotechnology Limited (Avecho) is today alerting Australians to recruitment efforts for the largest ever clinical trial (&apos;the Trial&apos;) for the treatment of insomnia with a pharmaceutical cannabidiol (CBD) product – with clinical trial sites now live across the country.</description>
    </item>
    <item>
      <title>June 2025 Quarterly Activities Report &amp; Appendix 4C</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/june-2025-quarterly-activities-report-and-appendix-4c-5</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/june-2025-quarterly-activities-report-and-appendix-4c-5</guid>
      <pubDate>Wed, 30 Jul 2025 03:05:15 GMT</pubDate>
      <description>June 2025 Quarterly Activities Report &amp; Appendix 4C</description>
    </item>
    <item>
      <title>Phase III Insomnia Trial Recruitment Update</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/phase-iii-insomnia-trial-recruitment-update</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/phase-iii-insomnia-trial-recruitment-update</guid>
      <pubDate>Tue, 29 Jul 2025 03:29:16 GMT</pubDate>
      <description>Phase III Insomnia Trial Recruitment Update</description>
    </item>
    <item>
      <title>Receipt of R&amp;D Tax Incentive</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/receipt-of-randd-tax-incentive</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/receipt-of-randd-tax-incentive</guid>
      <pubDate>Wed, 28 May 2025 05:45:09 GMT</pubDate>
      <description>Receipt of R&amp;D Tax Incentive</description>
    </item>
    <item>
      <title>Phase III Trial Update - New Sites Commence Recruitment</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/phase-iii-trial-update-new-sites-commence-recruitment</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/phase-iii-trial-update-new-sites-commence-recruitment</guid>
      <pubDate>Tue, 20 May 2025 03:23:16 GMT</pubDate>
      <description>Phase III Trial Update - New Sites Commence Recruitment</description>
    </item>
    <item>
      <title>March 2025 Quarterly Activities Report &amp; Appendix 4C</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/march-2025-quarterly-activities-report-and-appendix-4c-7</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/march-2025-quarterly-activities-report-and-appendix-4c-7</guid>
      <pubDate>Wed, 30 Apr 2025 04:28:20 GMT</pubDate>
      <description>March 2025 Quarterly Activities Report &amp; Appendix 4C</description>
    </item>
    <item>
      <title>Avecho receives initial US$3M upfront payment from Sandoz</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/avecho-receives-initial-usdollar3m-upfront-payment-from-sandoz</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/avecho-receives-initial-usdollar3m-upfront-payment-from-sandoz</guid>
      <pubDate>Fri, 28 Mar 2025 02:42:16 GMT</pubDate>
      <description>Avecho receives initial US$3M upfront payment from Sandoz</description>
    </item>
    <item>
      <title>Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/avecho-sandoz-enter-exclusive-license-220000509</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/avecho-sandoz-enter-exclusive-license-220000509</guid>
      <pubDate>Mon, 03 Mar 2025 22:00:00 GMT</pubDate>
      <description>Avecho Biotechnology Limited (ASX: AVE) (&quot;Avecho&quot; or the &quot;Company&quot;) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (&quot;Sandoz&quot;) for the commercial rights to Avecho&apos;s Phase III cannabidiol (&quot;CBD&quot;) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho&apos;s CBD capsule aims to be the first pharmaceutical CBD pro</description>
    </item>
    <item>
      <title>Avecho &amp; Sandoz Sign Deal to Develop CBD for Insomnia in AUS</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/avecho-and-sandoz-sign-deal-to-develop-cbd-for-insomnia-in-aus</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/avecho-and-sandoz-sign-deal-to-develop-cbd-for-insomnia-in-aus</guid>
      <pubDate>Mon, 03 Mar 2025 04:07:13 GMT</pubDate>
      <description>Avecho &amp; Sandoz Sign Deal to Develop CBD for Insomnia in AUS</description>
    </item>
    <item>
      <title>Trading Halt</title>
      <link>https://6ix.com/company/avecho-biotechnology-ltd/news/trading-halt-971</link>
      <guid isPermaLink="true">https://6ix.com/company/avecho-biotechnology-ltd/news/trading-halt-971</guid>
      <pubDate>Fri, 28 Feb 2025 03:13:25 GMT</pubDate>
      <description>Trading Halt</description>
    </item>
  </channel>
</rss>